BR112023022765A2 - Proteínas de ligação ao antígeno que ligam especificamente o prame - Google Patents

Proteínas de ligação ao antígeno que ligam especificamente o prame

Info

Publication number
BR112023022765A2
BR112023022765A2 BR112023022765A BR112023022765A BR112023022765A2 BR 112023022765 A2 BR112023022765 A2 BR 112023022765A2 BR 112023022765 A BR112023022765 A BR 112023022765A BR 112023022765 A BR112023022765 A BR 112023022765A BR 112023022765 A2 BR112023022765 A2 BR 112023022765A2
Authority
BR
Brazil
Prior art keywords
antigen
binding proteins
prame
specifically bind
nucleic acids
Prior art date
Application number
BR112023022765A
Other languages
English (en)
Inventor
Claudia Wagner
Dominik Maurer
Felix Unverdorben
Florian Schworer
Frank Schwobel
Gabriele Pszolla
Heiko Schuster
Maike Jaworski
Martin Hofmann
Meike Hutt
Sebastian Bunk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of BR112023022765A2 publication Critical patent/BR112023022765A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

proteínas de ligação ao antígeno que ligam especificamente o prame. a presente invenção refere-se a proteínas de ligação ao antígeno direcionadas contra antígenos derivados da proteína prame. a invenção, em particular, fornece proteínas de ligação ao antígeno que são específicas para o antígeno prame expresso por tumor, em que o antígeno tumoral compreende ou consiste em seq id no: 50 e se encontra em um complexo com uma proteína do complexo principal de histocompatibilidade (mhc). as proteínas de ligação ao antígeno da invenção contêm, em particular, as regiões determinantes de complementaridade (cdr) de novos receptores de células t (tcr) modificados que se ligam especificamente ao referido peptídeo de prame. as proteínas de ligação ao antígeno da invenção são para uso no diagnóstico, tratamento e prevenção de doenças cancerígenas que expressam prame. além disso, são fornecidos ácidos nucleicos que codificam as proteínas de ligação ao antígeno da invenção, vetores que compreendem esses ácidos nucleicos, células recombinantes que expressam as proteínas de ligação ao antígeno e composições farmacêuticas que compreendem as proteínas de ligação ao antígeno da invenção.
BR112023022765A 2021-05-05 2022-05-04 Proteínas de ligação ao antígeno que ligam especificamente o prame BR112023022765A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184689P 2021-05-05 2021-05-05
EP21172351 2021-05-05
PCT/EP2022/062017 WO2022233956A1 (en) 2021-05-05 2022-05-04 Antigen binding proteins specifically binding prame

Publications (1)

Publication Number Publication Date
BR112023022765A2 true BR112023022765A2 (pt) 2024-01-02

Family

ID=81579586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022765A BR112023022765A2 (pt) 2021-05-05 2022-05-04 Proteínas de ligação ao antígeno que ligam especificamente o prame

Country Status (13)

Country Link
US (4) US20220372165A1 (pt)
EP (1) EP4334361A1 (pt)
JP (1) JP2024518378A (pt)
KR (1) KR20240004935A (pt)
AU (1) AU2022270361A1 (pt)
BR (1) BR112023022765A2 (pt)
CA (1) CA3217738A1 (pt)
CL (1) CL2023003232A1 (pt)
CO (1) CO2023014722A2 (pt)
IL (1) IL308257A (pt)
MX (1) MX2023012902A (pt)
TW (1) TW202309071A (pt)
WO (1) WO2022233956A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554328B (zh) * 2023-05-11 2023-09-29 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种靶向trbv12的单链抗体、car、car-nk细胞及应用

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204A (en) 1847-07-24 james cantelo
US244A (en) 1837-06-30 Edward flint
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
ATE243745T1 (de) 1994-01-31 2003-07-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DE60040556D1 (de) 1999-12-06 2008-11-27 Univ Illinois Hochaffine t-zellrezeptorproteine und verfahren
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
EP2093286B1 (en) 2001-10-01 2013-02-27 Dyax Corporation Multi-chain eukaryotic display vectors and uses thereof
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
CA2505558C (en) 2002-11-09 2013-07-02 Avidex Limited T cell receptor display
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US7811828B2 (en) 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
KR20130114758A (ko) 2005-05-27 2013-10-17 오스페달레 산 라파엘 에스.알.엘. Ｍｉ-ｒｎａ를 포함하는 유전자 벡터
WO2006138568A2 (en) 2005-06-17 2006-12-28 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
EP2371851A3 (en) 2005-06-17 2012-08-01 Mannkind Corporation Epitope analogues
EP2385060A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2007106894A2 (en) 2006-03-15 2007-09-20 The Board Of Trustees Of The University Of Illinois Neutralizing agents for bacterial toxins
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
EP2079830B1 (en) 2006-10-04 2016-08-17 Janssen Pharmaceutica NV Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP2114993B1 (en) 2007-01-15 2012-08-29 GlaxoSmithKline Biologicals SA Vaccine
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
CA2700278A1 (en) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modified t cell receptors and related materials and methods
US20100317546A1 (en) 2008-01-11 2010-12-16 Morphosys Ag Display Vectors and Methods and Uses Thereof
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
ME02505B (me) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimerni vezujući proteini i njihove upotrebe
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
US9040669B2 (en) 2011-02-11 2015-05-26 Memorial Sloan Kettering Cancer Center HLA-restricted, peptide-specific antigen binding proteins
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
NZ704157A (en) 2012-07-27 2018-08-31 Univ Illinois Engineering t-cell receptors
CA2893918C (en) 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CA2904369A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
EP2970484B2 (en) 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
JP6405390B2 (ja) 2014-03-25 2018-10-17 メリアル インコーポレイテッド 弱毒ヒストフィルス・ソムニを含む免疫学的組成物
MX2016015383A (es) 2014-05-29 2017-02-28 Us Health Receptores de celulas t anti - papilomavirus 16 e7 humano.
EP3828265A1 (en) 2014-06-06 2021-06-02 Bluebird Bio, Inc. Improved t cell compositions
RU2747457C2 (ru) 2014-07-24 2021-05-05 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CN107428835B (zh) 2015-01-23 2021-11-26 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
ES2933030T3 (es) 2015-03-10 2023-01-31 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Receptores de células T dirigidos contra el antígeno de melanoma expresado preferencialmente y usos de los mismos
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
AU2016258845B2 (en) 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3297673A4 (en) * 2015-05-22 2019-05-08 Memorial Sloan-Kettering Cancer Center FOR A PRAME-PEPTIDE SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES
EP3353212B1 (en) 2015-09-23 2021-11-03 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
CN115927191A (zh) 2015-10-23 2023-04-07 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
EP3442576A4 (en) 2016-04-15 2020-05-13 Trustees of Dartmouth College HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS
JP6989138B2 (ja) 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体及びその使用
MX2018015937A (es) 2016-06-27 2019-05-02 Procter & Gamble Aparato y metodo para evaluar un tratamiento para la sensibilidad dental mediante producto para el cuidado bucal.
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
SG10201913959WA (en) 2016-08-02 2020-03-30 The United States Of America As Represented By The Secretary Anti-kras-g12d t cell receptors
US11325961B2 (en) 2016-08-05 2022-05-10 Tohoku University Natural killer cell function enhancer
CA3034873A1 (en) 2016-08-26 2018-03-01 Baylor College Of Medicine Constitutively active cytokine receptors for cell therapy
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
GB201617716D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc Cell
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
DE102016121899A1 (de) 2016-11-15 2018-05-17 Immatics Biotechnologies Gmbh Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
WO2018201047A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
CN111094333A (zh) 2017-06-01 2020-05-01 斯图加特大学 异源二聚化的Ig结构域
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
KR20200024905A (ko) 2017-07-04 2020-03-09 큐어백 아게 신규 핵산 분자
WO2019012141A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY
US20200261502A1 (en) 2017-09-08 2020-08-20 Carsgen Therapeutics Co., Ltd. Genetically engineered t cell and application thereof
AU2018337960A1 (en) 2017-09-20 2020-04-30 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
MX2020003145A (es) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos.
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
CN111511391A (zh) 2017-10-18 2020-08-07 英特拉克森公司 包含间隔区的多肽组合物
AU2018394353A1 (en) 2017-12-29 2020-07-09 Memorial Sloan-Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
EP3747456A4 (en) 2018-01-31 2021-12-01 Tohoku University PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN
CN111886243A (zh) 2018-02-11 2020-11-03 纪念斯隆-凯特琳癌症中心 非-hla限制性t细胞受体及其用途
CN110156889B (zh) 2018-02-14 2023-03-10 中国科学院广州生物医药与健康研究院 高亲和力HBs T细胞受体
MA52656A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
SG11202010262TA (en) 2018-04-19 2020-11-27 Baylor College Medicine Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
BR112020023195A2 (pt) 2018-05-14 2021-09-28 Immunocore Limited Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
CA3106056A1 (en) 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesu (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
MX2021002449A (es) 2018-09-04 2021-08-05 Treos Bio Ltd Vacunas peptidicas.
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
US20210380661A1 (en) 2018-10-16 2021-12-09 Texas Tech University System Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
WO2020097466A1 (en) 2018-11-08 2020-05-14 Neximmune, Inc. T cell compositions with improved phenotypic properties
SG11202105975SA (en) 2018-12-06 2021-07-29 Guangdong Tcrcure Biopharma Technology Co Ltd Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
US20220031750A1 (en) 2018-12-14 2022-02-03 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
CA3126064A1 (en) 2019-01-07 2020-07-16 Children's National Medical Center Improved targeted t-cell therapy for treatment of multiple myeloma
WO2020181142A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US12018061B2 (en) 2019-03-08 2024-06-25 St Phi Therapeutics Co., Ltd. Chimeric endocytic receptors and method of use thereof
WO2020186158A2 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
US20220153863A1 (en) 2019-03-13 2022-05-19 Hans David Staffan Ulmert Prame binding molecules and uses thereof
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3941490A4 (en) 2019-03-20 2023-01-04 2seventy bio, Inc. ADOPTIVE CELL THERAPY
EP3959307A4 (en) 2019-04-22 2023-08-23 Nanjing Legend Biotech Co., Ltd. GM CELLS AND USES THEREOF
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
JP2022534716A (ja) 2019-05-27 2022-08-03 イマティクス ユーエス，アイエヌシー． ウイルスベクターおよびその養子細胞療法における使用
US20210040558A1 (en) 2019-07-15 2021-02-11 Neogene Therapeutics B.V. Method to isolate tcr genes
CA3148072A1 (en) 2019-07-19 2021-01-28 Memorial Sloan-Kettering Cancer Center Fusion polypeptide for immunotherapy
EP4004042A1 (en) 2019-07-23 2022-06-01 Deutsches Krebsforschungszentrum Polypeptides for treatment of aml
WO2021016609A1 (en) 2019-07-24 2021-01-28 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
GB201911286D0 (en) 2019-08-07 2019-09-18 Ucl Business Plc Method
JP7483865B2 (ja) 2019-09-06 2024-05-15 イーライ リリー アンド カンパニー Ｔ細胞受容体の定常ドメインを含むタンパク質
US20220396635A1 (en) 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
US20210130495A1 (en) 2019-09-27 2021-05-06 Agenus Inc. Heterodimeric proteins
US20210147929A1 (en) 2019-10-11 2021-05-20 Saint Louis University Immune receptor analysis as diagnostic assay
IL292535A (en) 2019-11-15 2022-06-01 Gritstone Bio Inc Antigen-binding proteins that target shared neoantigens
BR112022009707A2 (pt) 2019-11-18 2022-08-09 BioNTech SE Receptores de tcr prame e usos dos mesmos
AU2020407591A1 (en) 2019-12-17 2022-06-23 The Johns Hopkins University Manabodies targeting tumor antigens and methods of using
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
AU2021220957A1 (en) 2020-02-14 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class I-restricted T cell receptors against ras with G12V mutation
CA3167496A1 (en) 2020-02-14 2021-08-19 Anne De Groot Regulatory t cell epitopes and detolerized sars-cov-2 antigens
AU2021225872A1 (en) 2020-02-26 2022-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted T cell receptors against RAS with G12V mutation
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2021188601A1 (en) 2020-03-16 2021-09-23 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
BR112022018359A2 (pt) 2020-03-16 2023-01-24 Univ Southern California Novos domínios de ligação ao antígeno e receptores de antígeno sintéticos incorporando os mesmos
WO2021211455A1 (en) 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
CN116171165A (zh) 2020-06-10 2023-05-26 墨尔本大学 Hiv-1抗体
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
US20230287079A1 (en) 2020-07-24 2023-09-14 Tscan Therapeutics, Inc. Binding proteins recognizing sars-cov-2 antigens and uses thereof
WO2022026358A1 (en) 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CA3195114A1 (en) 2020-10-09 2022-04-14 Martin Klatt Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
JP2023550515A (ja) 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体
CN116648256A (zh) 2020-12-21 2023-08-25 酵活生物制药有限公司 稳定化的tcr构建体及使用方法
US20220202862A1 (en) 2020-12-31 2022-06-30 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
WO2022150610A2 (en) 2021-01-08 2022-07-14 The Johns Hopkins University Sars-cov-2-specific t cell receptors and related materials and methods of use
WO2022178367A2 (en) 2021-02-19 2022-08-25 University Of Southern California Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Also Published As

Publication number Publication date
MX2023012902A (es) 2023-11-08
IL308257A (en) 2024-01-01
JP2024518378A (ja) 2024-05-01
US20240092933A1 (en) 2024-03-21
US20220372165A1 (en) 2022-11-24
US20230357428A1 (en) 2023-11-09
TW202309071A (zh) 2023-03-01
WO2022233956A1 (en) 2022-11-10
CL2023003232A1 (es) 2024-04-19
KR20240004935A (ko) 2024-01-11
AU2022270361A1 (en) 2023-11-16
EP4334361A1 (en) 2024-03-13
US11859009B2 (en) 2024-01-02
US20230091330A1 (en) 2023-03-23
CA3217738A1 (en) 2022-05-04
CO2023014722A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
CN108884136B (zh) 用于癌症免疫治疗的转染t细胞和t细胞受体
BR112022001923A2 (pt) Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno
TWI722660B (zh) 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
EP3666793A3 (en) Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1
CA3114451A1 (en) T cell receptor for identifying ssx2 antigen
CN116731156A (zh) 用于癌症免疫治疗的转染t细胞和t细胞受体
TW201841937A (zh) 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
JP2018509163A5 (pt)
EA037547B1 (ru) Способ активации хелперных т-клеток
US20210324034A1 (en) T cell receptor for identifying afp antigen
BR112023022765A2 (pt) Proteínas de ligação ao antígeno que ligam especificamente o prame
AU2017230855B2 (en) HLA-B57 open conformers
Ravindranath et al. The monospecificity of novel anti-HLA-E monoclonal antibodies enables reliable immunodiagnosis, immunomodulation of HLA-E, and upregulation of CD8+ T lymphocytes
CA3149010A1 (en) T cell receptor for identifying ssx2 antigen short peptide
TW201726714A (zh) 對於ｔｈ１細胞之ｃｄｃａ１抗原決定位胜肽及含此之疫苗
KR20110005833A (ko) Ｍｈｃ 클래스 ⅱ 분자에 제시되는 서바이빈의 부분 펩타이드 및 그의 용도
Ayyoub et al. Distinct but overlapping T helper epitopes in the 37–58 region of SSX-2
TW201106962A (en) CDC45L peptides and vaccines including the same
TW202140532A (zh) 一種辨識afp的t細胞受體及其編碼序列
AR125763A1 (es) Proteínas de unión a antígenos que se unen específicamente a prame
CN112121147B (zh) 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
US10849967B2 (en) Nucleic acid molecules encoding for chimeric CSPG4 proteins and therapeutic uses thereof
WO2021035446A1 (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
MX2023007713A (es) Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
EA043021B1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний